Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Vismodegib and sonidegib are Hedgehog pathway inhibitors (HPIs) approved for treatment of patients with advanced basal cell carcinoma. The adverse events (AEs) associated with these therapies can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation. The inc...

Full description

Bibliographic Details
Main Authors:	Lacouture, Mario E., Dréno, Brigitte, Ascierto, Paolo Antonio, Dummer, Reinhard, Basset-Seguin, Nicole, Fife, Kate, Ernst, Scott, Licitra, Lisa, Neves, Rogerio I., Peris, Ketty, Puig, Susana, Sokolof, Jonas, Sekulic, Aleksandar, Hauschild, Axel, Kunstfeld, Rainer
Format:	Online
Language:	English
Published:	AlphaMed Press 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061532/

id	pubmed-5061532
recordtype	oai_dc
spelling	pubmed-50615322017-04-01 Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma Lacouture, Mario E. Dréno, Brigitte Ascierto, Paolo Antonio Dummer, Reinhard Basset-Seguin, Nicole Fife, Kate Ernst, Scott Licitra, Lisa Neves, Rogerio I. Peris, Ketty Puig, Susana Sokolof, Jonas Sekulic, Aleksandar Hauschild, Axel Kunstfeld, Rainer Melanoma and Cutaneous Malignancies Vismodegib and sonidegib are Hedgehog pathway inhibitors (HPIs) approved for treatment of patients with advanced basal cell carcinoma. The adverse events (AEs) associated with these therapies can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation. The incidence, clinical presentation, putative mechanisms, and management strategies for AEs related to administration of HPIs are described in this article. AlphaMed Press 2016-10 2016-08-10 /pmc/articles/PMC5061532/ /pubmed/27511905 http://dx.doi.org/10.1634/theoncologist.2016-0186 Text en ©AlphaMed Press
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Lacouture, Mario E. Dréno, Brigitte Ascierto, Paolo Antonio Dummer, Reinhard Basset-Seguin, Nicole Fife, Kate Ernst, Scott Licitra, Lisa Neves, Rogerio I. Peris, Ketty Puig, Susana Sokolof, Jonas Sekulic, Aleksandar Hauschild, Axel Kunstfeld, Rainer
spellingShingle	Lacouture, Mario E. Dréno, Brigitte Ascierto, Paolo Antonio Dummer, Reinhard Basset-Seguin, Nicole Fife, Kate Ernst, Scott Licitra, Lisa Neves, Rogerio I. Peris, Ketty Puig, Susana Sokolof, Jonas Sekulic, Aleksandar Hauschild, Axel Kunstfeld, Rainer Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
author_facet	Lacouture, Mario E. Dréno, Brigitte Ascierto, Paolo Antonio Dummer, Reinhard Basset-Seguin, Nicole Fife, Kate Ernst, Scott Licitra, Lisa Neves, Rogerio I. Peris, Ketty Puig, Susana Sokolof, Jonas Sekulic, Aleksandar Hauschild, Axel Kunstfeld, Rainer
author_sort	Lacouture, Mario E.
title	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
title_short	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
title_full	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
title_fullStr	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
title_full_unstemmed	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
title_sort	characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma
description	Vismodegib and sonidegib are Hedgehog pathway inhibitors (HPIs) approved for treatment of patients with advanced basal cell carcinoma. The adverse events (AEs) associated with these therapies can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation. The incidence, clinical presentation, putative mechanisms, and management strategies for AEs related to administration of HPIs are described in this article.
publisher	AlphaMed Press
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061532/
_version_	1613681701867749376

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Similar Items